Navigation Links
New Methods Could Speed Production of Flu Vaccines
Date:5/18/2009

Clinical trials using new strategies show promise for better protection against flu

MONDAY, May 18 (HealthDay News) -- Vaccines made up of virus-like particles (VLPs) could provide stronger and longer-lasting protection against flu viruses than conventional vaccines, researchers say.

Even better, VLP vaccines, which can be grown in cell cultures or plants, can be developed and produced twice as quickly as conventional vaccines, according to research presented May 18 at the 109th General Meeting of the American Society for Microbiology, in Philadelphia.

In early clinical trials, VLP vaccines appear to provide complete protection against both the H5N1 avian influenza virus and the 1918 Spanish influenza virus, said Ted Ross, an assistant professor at the University of Pittsburgh's Center for Vaccine Research.

Adopting the new vaccine strategy may allow public health officials to respond more quickly to emerging influenza pandemics, according to a news release from the American Society for Microbiology.

"The sequence for the recent H1N1 'swine flu' virus was online and available to scientists long before physical samples could be delivered," Ross said in the news release. "It would have been possible to produce VLPs in quantity in as little as 12 weeks, while conventional vaccines require physical samples of the virus, and production can take approximately nine months."

Even without an actual sample of the agent, researchers can generate particles for a vaccine if the genes in the virus have been identified, Ross added.

Injectable vaccines that are currently in use to protect from the seasonal flu consist of three influenza strains that are grown in eggs and then inactivated using chemicals that break the virus up into pieces, according to background information provided in the news release. But because the pieces no longer look like the circulating virus, conventionally produced vaccines do not elicit as strong an immune response as VLPs.

"Virus-like particles look just like a live virus, but they are hollow shells without a genome inside, and they cannot reproduce," Ross said. "Because they look like the virus, they evoke a more robust immune response against the real thing."

Inhaled, mist-based flu vaccines can also elicit a strong immune response, but they are associated with an increased risk of side effects, because they are made with live, attenuated virus, the release noted.

Still, there is disagreement over who should be vaccinated and for what flu viruses, Ross said.

"There is a debate in the influenza community about priming the human population for potential pandemic strains such as H5N1 or 1918," Ross said. "Some researchers advocate adding these strains to the annual flu vaccine. They might not match the next pandemic flu strain exactly, but could provide some protection."

Others contend that it's premature and too costly to vaccinate people against a virus that may never emerge, he said.

More information

The CDC has more on flu vaccines.



-- Jennifer Thomas



SOURCE: American Society for Microbiology, news release, May 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Webcast Alert: Air Methods to Announce First Quarter 2009 Financial Results
2. Long Term Care Alerting Methods Revealed by Industry Leaders
3. Air Methods Preliminary 1st Qtr. Results Exceed Expectations
4. Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update
5. Air Methods to Report Fourth Quarter and Fiscal Year 2008 Financial Results on Tuesday, March 10, 2009
6. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
7. Early Detection Methods for Pancreatic Cancer Urgently Needed: A Statement From the Pancreatic Cancer Action Network
8. National Patient Advocate Foundation Founder Testifies Before U.S. Senate Health Committee on Methods to Improve Healthcare Quality and Patient Outcomes
9. Air Methods Provides 4th Quarter Update
10. Activator Methods Introduces Web-Based Seminar Program
11. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Methods Could Speed Production of Flu Vaccines 
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: